カテゴリー： 世界, 医療/バイオ, LP Information

世界の急性ウイルス性鼻副鼻腔炎治療市場予測 2023年-2029年

【英語タイトル】Global Acute Viral Rhinosinusitis Treatment Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC07356）・商品コード：LP23DC07356
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：122
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥556,320見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥834,480見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,112,640見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の急性ウイルス性鼻副鼻腔炎治療市場」は、過去の販売実績から2022年の世界の急性ウイルス性鼻副鼻腔炎治療の総販売量を検討し、2023年から2029年の予測される急性ウイルス性鼻副鼻腔炎治療の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の急性ウイルス性鼻副鼻腔炎治療の市場規模を掲載し、XXX百万米ドル規模の世界の急性ウイルス性鼻副鼻腔炎治療市場の詳細な分析を提供します。本インサイトレポートは、世界の急性ウイルス性鼻副鼻腔炎治療業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の急性ウイルス性鼻副鼻腔炎治療市場における各社の独自のポジションをより深く理解するために、急性ウイルス性鼻副鼻腔炎治療製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の急性ウイルス性鼻副鼻腔炎治療市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。急性ウイルス性鼻副鼻腔炎治療の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。急性ウイルス性鼻副鼻腔炎治療の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。急性ウイルス性鼻副鼻腔炎治療のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

急性ウイルス性鼻副鼻腔炎治療の世界主要メーカーとしては、Sun Pharmaceutical Industries, Inc.、 Pfizer, Inc.、 Johnson & Johnson、 Fresenius Kabi USA, LLC、 Dr. Reddy's Laboratories, Inc.、 Novartis AG、 Teva Pharmaceutical Industries Ltd.、 Sanofi、 Abbott Laboratories、 Bayer AG、 Eli Lilly and Company、 Bristol-Myers Squibb、 Merck & Co, Inc.、 AstraZeneca plc、 Amneal Pharmaceuticals LLC、 GlaxoSmithKline plc、 Aurobindo Pharma、 Hikma Pharmaceuticals plc、 Wockhardt、 Mylan N.V.などを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の急性ウイルス性鼻副鼻腔炎治療市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では急性ウイルス性鼻副鼻腔炎治療市場をセグメンテーションし、種類別 (非ステロイド性抗炎症薬、生理食塩水点鼻薬、鼻副腎皮質ステロイド、充血除去薬)、用途別 (オフライン薬局、電子商取引)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：非ステロイド性抗炎症薬、生理食塩水点鼻薬、鼻副腎皮質ステロイド、充血除去薬

・用途別区分：オフライン薬局、電子商取引

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の急性ウイルス性鼻副鼻腔炎治療市場の10年間の市場状況・展望は？
・世界および地域別に見た急性ウイルス性鼻副鼻腔炎治療市場成長の要因は何か？
・急性ウイルス性鼻副鼻腔炎治療の市場機会はエンドマーケットの規模によってどのように変化するのか？
・急性ウイルス性鼻副鼻腔炎治療のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：急性ウイルス性鼻副鼻腔炎治療の年間販売量2018-2029、地域別現状・将来分析
・急性ウイルス性鼻副鼻腔炎治療の種類別セグメント：非ステロイド性抗炎症薬、生理食塩水点鼻薬、鼻副腎皮質ステロイド、充血除去薬
・急性ウイルス性鼻副鼻腔炎治療の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・急性ウイルス性鼻副鼻腔炎治療の用途別セグメント：オフライン薬局、電子商取引
・急性ウイルス性鼻副鼻腔炎治療の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の急性ウイルス性鼻副鼻腔炎治療市場
・企業別のグローバル急性ウイルス性鼻副鼻腔炎治療市場データ：2018-2023年の年間販売量、市場シェア
・企業別の急性ウイルス性鼻副鼻腔炎治療の年間売上：2018-2023年の売上、市場シェア
・企業別の急性ウイルス性鼻副鼻腔炎治療販売価格
・主要企業の急性ウイルス性鼻副鼻腔炎治療生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

急性ウイルス性鼻副鼻腔炎治療の地域別レビュー
・地域別の急性ウイルス性鼻副鼻腔炎治療市場規模2018-2023：年間販売量、売上
・主要国別の急性ウイルス性鼻副鼻腔炎治療市場規模2018-2023：年間販売量、売上
・南北アメリカの急性ウイルス性鼻副鼻腔炎治療販売の成長
・アジア太平洋の急性ウイルス性鼻副鼻腔炎治療販売の成長
・ヨーロッパの急性ウイルス性鼻副鼻腔炎治療販売の成長
・中東・アフリカの急性ウイルス性鼻副鼻腔炎治療販売の成長

南北アメリカ市場
・南北アメリカの国別の急性ウイルス性鼻副鼻腔炎治療販売量、売上（2018-2023）
・南北アメリカの急性ウイルス性鼻副鼻腔炎治療の種類別販売量
・南北アメリカの急性ウイルス性鼻副鼻腔炎治療の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の急性ウイルス性鼻副鼻腔炎治療販売量、売上（2018-2023）
・アジア太平洋の急性ウイルス性鼻副鼻腔炎治療の種類別販売量
・アジア太平洋の急性ウイルス性鼻副鼻腔炎治療の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の急性ウイルス性鼻副鼻腔炎治療販売量、売上（2018-2023）
・ヨーロッパの急性ウイルス性鼻副鼻腔炎治療の種類別販売量
・ヨーロッパの急性ウイルス性鼻副鼻腔炎治療の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の急性ウイルス性鼻副鼻腔炎治療販売量、売上（2018-2023）
・中東・アフリカの急性ウイルス性鼻副鼻腔炎治療の種類別販売量
・中東・アフリカの急性ウイルス性鼻副鼻腔炎治療の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・急性ウイルス性鼻副鼻腔炎治療の製造コスト構造分析
・急性ウイルス性鼻副鼻腔炎治療の製造プロセス分析
・急性ウイルス性鼻副鼻腔炎治療の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・急性ウイルス性鼻副鼻腔炎治療の主要なグローバル販売業者
・急性ウイルス性鼻副鼻腔炎治療の主要なグローバル顧客

地域別の急性ウイルス性鼻副鼻腔炎治療市場予測レビュー
・地域別の急性ウイルス性鼻副鼻腔炎治療市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・急性ウイルス性鼻副鼻腔炎治療の種類別市場規模予測
・急性ウイルス性鼻副鼻腔炎治療の用途別市場規模予測

主要企業分析
Sun Pharmaceutical Industries, Inc.、 Pfizer, Inc.、 Johnson & Johnson、 Fresenius Kabi USA, LLC、 Dr. Reddy's Laboratories, Inc.、 Novartis AG、 Teva Pharmaceutical Industries Ltd.、 Sanofi、 Abbott Laboratories、 Bayer AG、 Eli Lilly and Company、 Bristol-Myers Squibb、 Merck & Co, Inc.、 AstraZeneca plc、 Amneal Pharmaceuticals LLC、 GlaxoSmithKline plc、 Aurobindo Pharma、 Hikma Pharmaceuticals plc、 Wockhardt、 Mylan N.V.
・企業情報
・急性ウイルス性鼻副鼻腔炎治療製品
・急性ウイルス性鼻副鼻腔炎治療販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Acute Viral Rhinosinusitis Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Acute Viral Rhinosinusitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Acute Viral Rhinosinusitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Acute Viral Rhinosinusitis Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Acute Viral Rhinosinusitis Treatment players cover Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Johnson & Johnson, Fresenius Kabi USA, LLC, Dr. Reddy’s Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi and Abbott Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Acute viral sinusitis refers to sinus cavity inflammation caused by viral infection. The sinuses are cavities in the face of the head and are divided into the frontal, ethmoid, sphenoid, and maxillary sinuses. Viral sinusitis is often one of the symptoms of a cold, because the cold virus enters the sinus cavity through the nasal mucosa and causes an inflammatory response.
LPI (LP Information)’ newest research report, the “Acute Viral Rhinosinusitis Treatment Industry Forecast” looks at past sales and reviews total world Acute Viral Rhinosinusitis Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Acute Viral Rhinosinusitis Treatment sales for 2023 through 2029. With Acute Viral Rhinosinusitis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Acute Viral Rhinosinusitis Treatment industry.
This Insight Report provides a comprehensive analysis of the global Acute Viral Rhinosinusitis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Acute Viral Rhinosinusitis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Acute Viral Rhinosinusitis Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Acute Viral Rhinosinusitis Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Acute Viral Rhinosinusitis Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Acute Viral Rhinosinusitis Treatment market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
NSAIDS
Saline Nasal Spray
Nasal Corticosteroids
Decongestants
Segmentation by application
Offline Pharmacy
E-Commerce
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Sun Pharmaceutical Industries, Inc.
Pfizer, Inc.
Johnson & Johnson
Fresenius Kabi USA, LLC
Dr. Reddy’s Laboratories, Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Sanofi
Abbott Laboratories
Bayer AG
Eli Lilly and Company
Bristol-Myers Squibb
Merck & Co, Inc.
AstraZeneca plc
Amneal Pharmaceuticals LLC
GlaxoSmithKline plc
Aurobindo Pharma
Hikma Pharmaceuticals plc
Wockhardt
Mylan N.V.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Acute Viral Rhinosinusitis Treatment market?
What factors are driving Acute Viral Rhinosinusitis Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Acute Viral Rhinosinusitis Treatment market opportunities vary by end market size?
How does Acute Viral Rhinosinusitis Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Acute Viral Rhinosinusitis Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Acute Viral Rhinosinusitis Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Acute Viral Rhinosinusitis Treatment by Country/Region, 2018, 2022 & 2029
2.2 Acute Viral Rhinosinusitis Treatment Segment by Type
2.2.1 NSAIDS
2.2.2 Saline Nasal Spray
2.2.3 Nasal Corticosteroids
2.2.4 Decongestants
2.3 Acute Viral Rhinosinusitis Treatment Sales by Type
2.3.1 Global Acute Viral Rhinosinusitis Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Acute Viral Rhinosinusitis Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Acute Viral Rhinosinusitis Treatment Sale Price by Type (2018-2023)
2.4 Acute Viral Rhinosinusitis Treatment Segment by Application
2.4.1 Offline Pharmacy
2.4.2 E-Commerce
2.5 Acute Viral Rhinosinusitis Treatment Sales by Application
2.5.1 Global Acute Viral Rhinosinusitis Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Acute Viral Rhinosinusitis Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Acute Viral Rhinosinusitis Treatment Sale Price by Application (2018-2023)
3 Global Acute Viral Rhinosinusitis Treatment by Company
3.1 Global Acute Viral Rhinosinusitis Treatment Breakdown Data by Company
3.1.1 Global Acute Viral Rhinosinusitis Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Acute Viral Rhinosinusitis Treatment Sales Market Share by Company (2018-2023)
3.2 Global Acute Viral Rhinosinusitis Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Acute Viral Rhinosinusitis Treatment Revenue by Company (2018-2023)
3.2.2 Global Acute Viral Rhinosinusitis Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Acute Viral Rhinosinusitis Treatment Sale Price by Company
3.4 Key Manufacturers Acute Viral Rhinosinusitis Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Acute Viral Rhinosinusitis Treatment Product Location Distribution
3.4.2 Players Acute Viral Rhinosinusitis Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Acute Viral Rhinosinusitis Treatment by Geographic Region
4.1 World Historic Acute Viral Rhinosinusitis Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Acute Viral Rhinosinusitis Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Acute Viral Rhinosinusitis Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Acute Viral Rhinosinusitis Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Acute Viral Rhinosinusitis Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Acute Viral Rhinosinusitis Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Acute Viral Rhinosinusitis Treatment Sales Growth
4.4 APAC Acute Viral Rhinosinusitis Treatment Sales Growth
4.5 Europe Acute Viral Rhinosinusitis Treatment Sales Growth
4.6 Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Growth
5 Americas
5.1 Americas Acute Viral Rhinosinusitis Treatment Sales by Country
5.1.1 Americas Acute Viral Rhinosinusitis Treatment Sales by Country (2018-2023)
5.1.2 Americas Acute Viral Rhinosinusitis Treatment Revenue by Country (2018-2023)
5.2 Americas Acute Viral Rhinosinusitis Treatment Sales by Type
5.3 Americas Acute Viral Rhinosinusitis Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Acute Viral Rhinosinusitis Treatment Sales by Region
6.1.1 APAC Acute Viral Rhinosinusitis Treatment Sales by Region (2018-2023)
6.1.2 APAC Acute Viral Rhinosinusitis Treatment Revenue by Region (2018-2023)
6.2 APAC Acute Viral Rhinosinusitis Treatment Sales by Type
6.3 APAC Acute Viral Rhinosinusitis Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Acute Viral Rhinosinusitis Treatment by Country
7.1.1 Europe Acute Viral Rhinosinusitis Treatment Sales by Country (2018-2023)
7.1.2 Europe Acute Viral Rhinosinusitis Treatment Revenue by Country (2018-2023)
7.2 Europe Acute Viral Rhinosinusitis Treatment Sales by Type
7.3 Europe Acute Viral Rhinosinusitis Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Acute Viral Rhinosinusitis Treatment by Country
8.1.1 Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Acute Viral Rhinosinusitis Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales by Type
8.3 Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Acute Viral Rhinosinusitis Treatment
10.3 Manufacturing Process Analysis of Acute Viral Rhinosinusitis Treatment
10.4 Industry Chain Structure of Acute Viral Rhinosinusitis Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Acute Viral Rhinosinusitis Treatment Distributors
11.3 Acute Viral Rhinosinusitis Treatment Customer
12 World Forecast Review for Acute Viral Rhinosinusitis Treatment by Geographic Region
12.1 Global Acute Viral Rhinosinusitis Treatment Market Size Forecast by Region
12.1.1 Global Acute Viral Rhinosinusitis Treatment Forecast by Region (2024-2029)
12.1.2 Global Acute Viral Rhinosinusitis Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Acute Viral Rhinosinusitis Treatment Forecast by Type
12.7 Global Acute Viral Rhinosinusitis Treatment Forecast by Application
13 Key Players Analysis
13.1 Sun Pharmaceutical Industries, Inc.
13.1.1 Sun Pharmaceutical Industries, Inc. Company Information
13.1.2 Sun Pharmaceutical Industries, Inc. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.1.3 Sun Pharmaceutical Industries, Inc. Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sun Pharmaceutical Industries, Inc. Main Business Overview
13.1.5 Sun Pharmaceutical Industries, Inc. Latest Developments
13.2 Pfizer, Inc.
13.2.1 Pfizer, Inc. Company Information
13.2.2 Pfizer, Inc. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.2.3 Pfizer, Inc. Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Pfizer, Inc. Main Business Overview
13.2.5 Pfizer, Inc. Latest Developments
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Information
13.3.2 Johnson & Johnson Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.3.3 Johnson & Johnson Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Johnson & Johnson Main Business Overview
13.3.5 Johnson & Johnson Latest Developments
13.4 Fresenius Kabi USA, LLC
13.4.1 Fresenius Kabi USA, LLC Company Information
13.4.2 Fresenius Kabi USA, LLC Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.4.3 Fresenius Kabi USA, LLC Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Fresenius Kabi USA, LLC Main Business Overview
13.4.5 Fresenius Kabi USA, LLC Latest Developments
13.5 Dr. Reddy’s Laboratories, Inc.
13.5.1 Dr. Reddy’s Laboratories, Inc. Company Information
13.5.2 Dr. Reddy’s Laboratories, Inc. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.5.3 Dr. Reddy’s Laboratories, Inc. Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Dr. Reddy’s Laboratories, Inc. Main Business Overview
13.5.5 Dr. Reddy’s Laboratories, Inc. Latest Developments
13.6 Novartis AG
13.6.1 Novartis AG Company Information
13.6.2 Novartis AG Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.6.3 Novartis AG Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Novartis AG Main Business Overview
13.6.5 Novartis AG Latest Developments
13.7 Teva Pharmaceutical Industries Ltd.
13.7.1 Teva Pharmaceutical Industries Ltd. Company Information
13.7.2 Teva Pharmaceutical Industries Ltd. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.7.3 Teva Pharmaceutical Industries Ltd. Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
13.7.5 Teva Pharmaceutical Industries Ltd. Latest Developments
13.8 Sanofi
13.8.1 Sanofi Company Information
13.8.2 Sanofi Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.8.3 Sanofi Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sanofi Main Business Overview
13.8.5 Sanofi Latest Developments
13.9 Abbott Laboratories
13.9.1 Abbott Laboratories Company Information
13.9.2 Abbott Laboratories Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.9.3 Abbott Laboratories Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Abbott Laboratories Main Business Overview
13.9.5 Abbott Laboratories Latest Developments
13.10 Bayer AG
13.10.1 Bayer AG Company Information
13.10.2 Bayer AG Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.10.3 Bayer AG Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Bayer AG Main Business Overview
13.10.5 Bayer AG Latest Developments
13.11 Eli Lilly and Company
13.11.1 Eli Lilly and Company Company Information
13.11.2 Eli Lilly and Company Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.11.3 Eli Lilly and Company Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Eli Lilly and Company Main Business Overview
13.11.5 Eli Lilly and Company Latest Developments
13.12 Bristol-Myers Squibb
13.12.1 Bristol-Myers Squibb Company Information
13.12.2 Bristol-Myers Squibb Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.12.3 Bristol-Myers Squibb Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Bristol-Myers Squibb Main Business Overview
13.12.5 Bristol-Myers Squibb Latest Developments
13.13 Merck & Co, Inc.
13.13.1 Merck & Co, Inc. Company Information
13.13.2 Merck & Co, Inc. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.13.3 Merck & Co, Inc. Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Merck & Co, Inc. Main Business Overview
13.13.5 Merck & Co, Inc. Latest Developments
13.14 AstraZeneca plc
13.14.1 AstraZeneca plc Company Information
13.14.2 AstraZeneca plc Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.14.3 AstraZeneca plc Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 AstraZeneca plc Main Business Overview
13.14.5 AstraZeneca plc Latest Developments
13.15 Amneal Pharmaceuticals LLC
13.15.1 Amneal Pharmaceuticals LLC Company Information
13.15.2 Amneal Pharmaceuticals LLC Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.15.3 Amneal Pharmaceuticals LLC Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Amneal Pharmaceuticals LLC Main Business Overview
13.15.5 Amneal Pharmaceuticals LLC Latest Developments
13.16 GlaxoSmithKline plc
13.16.1 GlaxoSmithKline plc Company Information
13.16.2 GlaxoSmithKline plc Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.16.3 GlaxoSmithKline plc Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 GlaxoSmithKline plc Main Business Overview
13.16.5 GlaxoSmithKline plc Latest Developments
13.17 Aurobindo Pharma
13.17.1 Aurobindo Pharma Company Information
13.17.2 Aurobindo Pharma Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.17.3 Aurobindo Pharma Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Aurobindo Pharma Main Business Overview
13.17.5 Aurobindo Pharma Latest Developments
13.18 Hikma Pharmaceuticals plc
13.18.1 Hikma Pharmaceuticals plc Company Information
13.18.2 Hikma Pharmaceuticals plc Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.18.3 Hikma Pharmaceuticals plc Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Hikma Pharmaceuticals plc Main Business Overview
13.18.5 Hikma Pharmaceuticals plc Latest Developments
13.19 Wockhardt
13.19.1 Wockhardt Company Information
13.19.2 Wockhardt Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.19.3 Wockhardt Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Wockhardt Main Business Overview
13.19.5 Wockhardt Latest Developments
13.20 Mylan N.V.
13.20.1 Mylan N.V. Company Information
13.20.2 Mylan N.V. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
13.20.3 Mylan N.V. Acute Viral Rhinosinusitis Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Mylan N.V. Main Business Overview
13.20.5 Mylan N.V. Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Acute Viral Rhinosinusitis Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Acute Viral Rhinosinusitis Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of NSAIDS
Table 4. Major Players of Saline Nasal Spray
Table 5. Major Players of Nasal Corticosteroids
Table 6. Major Players of Decongestants
Table 7. Global Acute Viral Rhinosinusitis Treatment Sales by Type (2018-2023) & (K Units)
Table 8. Global Acute Viral Rhinosinusitis Treatment Sales Market Share by Type (2018-2023)
Table 9. Global Acute Viral Rhinosinusitis Treatment Revenue by Type (2018-2023) & ($ million)
Table 10. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share by Type (2018-2023)
Table 11. Global Acute Viral Rhinosinusitis Treatment Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Acute Viral Rhinosinusitis Treatment Sales by Application (2018-2023) & (K Units)
Table 13. Global Acute Viral Rhinosinusitis Treatment Sales Market Share by Application (2018-2023)
Table 14. Global Acute Viral Rhinosinusitis Treatment Revenue by Application (2018-2023)
Table 15. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share by Application (2018-2023)
Table 16. Global Acute Viral Rhinosinusitis Treatment Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Acute Viral Rhinosinusitis Treatment Sales by Company (2018-2023) & (K Units)
Table 18. Global Acute Viral Rhinosinusitis Treatment Sales Market Share by Company (2018-2023)
Table 19. Global Acute Viral Rhinosinusitis Treatment Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share by Company (2018-2023)
Table 21. Global Acute Viral Rhinosinusitis Treatment Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Acute Viral Rhinosinusitis Treatment Producing Area Distribution and Sales Area
Table 23. Players Acute Viral Rhinosinusitis Treatment Products Offered
Table 24. Acute Viral Rhinosinusitis Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Acute Viral Rhinosinusitis Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Acute Viral Rhinosinusitis Treatment Sales Market Share Geographic Region (2018-2023)
Table 29. Global Acute Viral Rhinosinusitis Treatment Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Acute Viral Rhinosinusitis Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Acute Viral Rhinosinusitis Treatment Sales Market Share by Country/Region (2018-2023)
Table 33. Global Acute Viral Rhinosinusitis Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Acute Viral Rhinosinusitis Treatment Sales by Country (2018-2023) & (K Units)
Table 36. Americas Acute Viral Rhinosinusitis Treatment Sales Market Share by Country (2018-2023)
Table 37. Americas Acute Viral Rhinosinusitis Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Acute Viral Rhinosinusitis Treatment Revenue Market Share by Country (2018-2023)
Table 39. Americas Acute Viral Rhinosinusitis Treatment Sales by Type (2018-2023) & (K Units)
Table 40. Americas Acute Viral Rhinosinusitis Treatment Sales by Application (2018-2023) & (K Units)
Table 41. APAC Acute Viral Rhinosinusitis Treatment Sales by Region (2018-2023) & (K Units)
Table 42. APAC Acute Viral Rhinosinusitis Treatment Sales Market Share by Region (2018-2023)
Table 43. APAC Acute Viral Rhinosinusitis Treatment Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Acute Viral Rhinosinusitis Treatment Revenue Market Share by Region (2018-2023)
Table 45. APAC Acute Viral Rhinosinusitis Treatment Sales by Type (2018-2023) & (K Units)
Table 46. APAC Acute Viral Rhinosinusitis Treatment Sales by Application (2018-2023) & (K Units)
Table 47. Europe Acute Viral Rhinosinusitis Treatment Sales by Country (2018-2023) & (K Units)
Table 48. Europe Acute Viral Rhinosinusitis Treatment Sales Market Share by Country (2018-2023)
Table 49. Europe Acute Viral Rhinosinusitis Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Acute Viral Rhinosinusitis Treatment Revenue Market Share by Country (2018-2023)
Table 51. Europe Acute Viral Rhinosinusitis Treatment Sales by Type (2018-2023) & (K Units)
Table 52. Europe Acute Viral Rhinosinusitis Treatment Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Acute Viral Rhinosinusitis Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Acute Viral Rhinosinusitis Treatment Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Acute Viral Rhinosinusitis Treatment
Table 60. Key Market Challenges & Risks of Acute Viral Rhinosinusitis Treatment
Table 61. Key Industry Trends of Acute Viral Rhinosinusitis Treatment
Table 62. Acute Viral Rhinosinusitis Treatment Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Acute Viral Rhinosinusitis Treatment Distributors List
Table 65. Acute Viral Rhinosinusitis Treatment Customer List
Table 66. Global Acute Viral Rhinosinusitis Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Acute Viral Rhinosinusitis Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Acute Viral Rhinosinusitis Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Acute Viral Rhinosinusitis Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Acute Viral Rhinosinusitis Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Acute Viral Rhinosinusitis Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Acute Viral Rhinosinusitis Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Acute Viral Rhinosinusitis Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Acute Viral Rhinosinusitis Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Acute Viral Rhinosinusitis Treatment Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Acute Viral Rhinosinusitis Treatment Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Acute Viral Rhinosinusitis Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Acute Viral Rhinosinusitis Treatment Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Sun Pharmaceutical Industries, Inc. Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 81. Sun Pharmaceutical Industries, Inc. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 82. Sun Pharmaceutical Industries, Inc. Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Sun Pharmaceutical Industries, Inc. Main Business
Table 84. Sun Pharmaceutical Industries, Inc. Latest Developments
Table 85. Pfizer, Inc. Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 86. Pfizer, Inc. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 87. Pfizer, Inc. Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Pfizer, Inc. Main Business
Table 89. Pfizer, Inc. Latest Developments
Table 90. Johnson & Johnson Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 91. Johnson & Johnson Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 92. Johnson & Johnson Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Johnson & Johnson Main Business
Table 94. Johnson & Johnson Latest Developments
Table 95. Fresenius Kabi USA, LLC Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 96. Fresenius Kabi USA, LLC Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 97. Fresenius Kabi USA, LLC Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Fresenius Kabi USA, LLC Main Business
Table 99. Fresenius Kabi USA, LLC Latest Developments
Table 100. Dr. Reddy's Laboratories, Inc. Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 101. Dr. Reddy's Laboratories, Inc. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 102. Dr. Reddy's Laboratories, Inc. Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Dr. Reddy's Laboratories, Inc. Main Business
Table 104. Dr. Reddy's Laboratories, Inc. Latest Developments
Table 105. Novartis AG Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 106. Novartis AG Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 107. Novartis AG Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Novartis AG Main Business
Table 109. Novartis AG Latest Developments
Table 110. Teva Pharmaceutical Industries Ltd. Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 111. Teva Pharmaceutical Industries Ltd. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 112. Teva Pharmaceutical Industries Ltd. Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Teva Pharmaceutical Industries Ltd. Main Business
Table 114. Teva Pharmaceutical Industries Ltd. Latest Developments
Table 115. Sanofi Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 116. Sanofi Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 117. Sanofi Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Sanofi Main Business
Table 119. Sanofi Latest Developments
Table 120. Abbott Laboratories Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 121. Abbott Laboratories Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 122. Abbott Laboratories Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Abbott Laboratories Main Business
Table 124. Abbott Laboratories Latest Developments
Table 125. Bayer AG Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 126. Bayer AG Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 127. Bayer AG Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Bayer AG Main Business
Table 129. Bayer AG Latest Developments
Table 130. Eli Lilly and Company Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 131. Eli Lilly and Company Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 132. Eli Lilly and Company Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Eli Lilly and Company Main Business
Table 134. Eli Lilly and Company Latest Developments
Table 135. Bristol-Myers Squibb Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 136. Bristol-Myers Squibb Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 137. Bristol-Myers Squibb Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Bristol-Myers Squibb Main Business
Table 139. Bristol-Myers Squibb Latest Developments
Table 140. Merck & Co, Inc. Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 141. Merck & Co, Inc. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 142. Merck & Co, Inc. Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. Merck & Co, Inc. Main Business
Table 144. Merck & Co, Inc. Latest Developments
Table 145. AstraZeneca plc Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 146. AstraZeneca plc Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 147. AstraZeneca plc Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 148. AstraZeneca plc Main Business
Table 149. AstraZeneca plc Latest Developments
Table 150. Amneal Pharmaceuticals LLC Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 151. Amneal Pharmaceuticals LLC Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 152. Amneal Pharmaceuticals LLC Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 153. Amneal Pharmaceuticals LLC Main Business
Table 154. Amneal Pharmaceuticals LLC Latest Developments
Table 155. GlaxoSmithKline plc Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 156. GlaxoSmithKline plc Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 157. GlaxoSmithKline plc Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 158. GlaxoSmithKline plc Main Business
Table 159. GlaxoSmithKline plc Latest Developments
Table 160. Aurobindo Pharma Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 161. Aurobindo Pharma Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 162. Aurobindo Pharma Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 163. Aurobindo Pharma Main Business
Table 164. Aurobindo Pharma Latest Developments
Table 165. Hikma Pharmaceuticals plc Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 166. Hikma Pharmaceuticals plc Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 167. Hikma Pharmaceuticals plc Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 168. Hikma Pharmaceuticals plc Main Business
Table 169. Hikma Pharmaceuticals plc Latest Developments
Table 170. Wockhardt Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 171. Wockhardt Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 172. Wockhardt Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 173. Wockhardt Main Business
Table 174. Wockhardt Latest Developments
Table 175. Mylan N.V. Basic Information, Acute Viral Rhinosinusitis Treatment Manufacturing Base, Sales Area and Its Competitors
Table 176. Mylan N.V. Acute Viral Rhinosinusitis Treatment Product Portfolios and Specifications
Table 177. Mylan N.V. Acute Viral Rhinosinusitis Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 178. Mylan N.V. Main Business
Table 179. Mylan N.V. Latest Developments
List of Figures
Figure 1. Picture of Acute Viral Rhinosinusitis Treatment
Figure 2. Acute Viral Rhinosinusitis Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Acute Viral Rhinosinusitis Treatment Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Acute Viral Rhinosinusitis Treatment Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Acute Viral Rhinosinusitis Treatment Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of NSAIDS
Figure 10. Product Picture of Saline Nasal Spray
Figure 11. Product Picture of Nasal Corticosteroids
Figure 12. Product Picture of Decongestants
Figure 13. Global Acute Viral Rhinosinusitis Treatment Sales Market Share by Type in 2022
Figure 14. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share by Type (2018-2023)
Figure 15. Acute Viral Rhinosinusitis Treatment Consumed in Offline Pharmacy
Figure 16. Global Acute Viral Rhinosinusitis Treatment Market: Offline Pharmacy (2018-2023) & (K Units)
Figure 17. Acute Viral Rhinosinusitis Treatment Consumed in E-Commerce
Figure 18. Global Acute Viral Rhinosinusitis Treatment Market: E-Commerce (2018-2023) & (K Units)
Figure 19. Global Acute Viral Rhinosinusitis Treatment Sales Market Share by Application (2022)
Figure 20. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share by Application in 2022
Figure 21. Acute Viral Rhinosinusitis Treatment Sales Market by Company in 2022 (K Units)
Figure 22. Global Acute Viral Rhinosinusitis Treatment Sales Market Share by Company in 2022
Figure 23. Acute Viral Rhinosinusitis Treatment Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share by Company in 2022
Figure 25. Global Acute Viral Rhinosinusitis Treatment Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Acute Viral Rhinosinusitis Treatment Sales 2018-2023 (K Units)
Figure 28. Americas Acute Viral Rhinosinusitis Treatment Revenue 2018-2023 ($ Millions)
Figure 29. APAC Acute Viral Rhinosinusitis Treatment Sales 2018-2023 (K Units)
Figure 30. APAC Acute Viral Rhinosinusitis Treatment Revenue 2018-2023 ($ Millions)
Figure 31. Europe Acute Viral Rhinosinusitis Treatment Sales 2018-2023 (K Units)
Figure 32. Europe Acute Viral Rhinosinusitis Treatment Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Acute Viral Rhinosinusitis Treatment Revenue 2018-2023 ($ Millions)
Figure 35. Americas Acute Viral Rhinosinusitis Treatment Sales Market Share by Country in 2022
Figure 36. Americas Acute Viral Rhinosinusitis Treatment Revenue Market Share by Country in 2022
Figure 37. Americas Acute Viral Rhinosinusitis Treatment Sales Market Share by Type (2018-2023)
Figure 38. Americas Acute Viral Rhinosinusitis Treatment Sales Market Share by Application (2018-2023)
Figure 39. United States Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Acute Viral Rhinosinusitis Treatment Sales Market Share by Region in 2022
Figure 44. APAC Acute Viral Rhinosinusitis Treatment Revenue Market Share by Regions in 2022
Figure 45. APAC Acute Viral Rhinosinusitis Treatment Sales Market Share by Type (2018-2023)
Figure 46. APAC Acute Viral Rhinosinusitis Treatment Sales Market Share by Application (2018-2023)
Figure 47. China Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Acute Viral Rhinosinusitis Treatment Sales Market Share by Country in 2022
Figure 55. Europe Acute Viral Rhinosinusitis Treatment Revenue Market Share by Country in 2022
Figure 56. Europe Acute Viral Rhinosinusitis Treatment Sales Market Share by Type (2018-2023)
Figure 57. Europe Acute Viral Rhinosinusitis Treatment Sales Market Share by Application (2018-2023)
Figure 58. Germany Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Acute Viral Rhinosinusitis Treatment Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Market Share by Application (2018-2023)
Figure 67. Egypt Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Acute Viral Rhinosinusitis Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Acute Viral Rhinosinusitis Treatment in 2022
Figure 73. Manufacturing Process Analysis of Acute Viral Rhinosinusitis Treatment
Figure 74. Industry Chain Structure of Acute Viral Rhinosinusitis Treatment
Figure 75. Channels of Distribution
Figure 76. Global Acute Viral Rhinosinusitis Treatment Sales Market Forecast by Region (2024-2029)
Figure 77. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Acute Viral Rhinosinusitis Treatment Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Acute Viral Rhinosinusitis Treatment Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Acute Viral Rhinosinusitis Treatment Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の急性ウイルス性鼻副鼻腔炎治療市場予測 2023年-2029年] (コード：LP23DC07356)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の急性ウイルス性鼻副鼻腔炎治療市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の多汗症治療用ボトックス市場予測 2023年-2029年
  • 世界の矯正治療用製品市場予測 2023年-2029年
  • 世界の髄膜炎菌性髄膜炎用治療市場予測 2023年-2029年
  • 世界の静脈性潰瘍用治療市場予測 2023年-2029年
  • 世界のシュニッツラー症候群治療市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆